P
PRECISION BIOSCIENCES INC
NASDAQ: DTIL (Precision BioSciences, Inc.)
最近更新时间: 22小时之前7.17
-0.07 (-0.97%)
| 前收盘价格 | 7.24 |
| 成交量 | 191,403 |
| 预期市盈率 (P/E Forward) | 11.78 |
| 价格/销量 (P/S) | 3.24 |
| 股市价格/股市净资产 (P/B) | 4.37 |
| 52周波幅 |
| 营业毛利率 | -42.99% |
| 营业利益率 (TTM) | -76,248.27% |
| 稀释每股收益 (EPS TTM) | -2.87 |
| 季度收入增长率 (YOY) | -99.80% |
| 总债务/股东权益 (D/E MRQ) | 60.30% |
| 流动比率 (MRQ) | 6.62 |
| 营业现金流 (OCF TTM) | -58.52 M |
| 杠杆自由现金流 (LFCF TTM) | 6.86 M |
| 资产报酬率 (ROA TTM) | -17.83% |
| 股东权益报酬率 (ROE TTM) | -50.81% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Precision BioSciences, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
-0.8
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.83 |
|
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 10.94% |
| 机构持股比例 | 42.73% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Octagon Capital Advisors Lp | 30 Jun 2026 | 1,350,000 |
| Empery Asset Management, Lp | 30 Jun 2026 | 776,093 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合